| Sipuleucel-T immunotherapy for castration-resistant prostate cancer PW Kantoff, CS Higano, ND Shore, ER Berger, EJ Small, DF Penson, ... New England Journal of Medicine 363 (5), 411-422, 2010 | 6829 | 2010 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3477 | 2014 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3287 | 2013 |
| Development of a second-generation antiandrogen for treatment of advanced prostate cancer C Tran, S Ouk, NJ Clegg, Y Chen, PA Watson, V Arora, J Wongvipat, ... Science 324 (5928), 787-790, 2009 | 2728 | 2009 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2482 | 2008 |
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer EJ Small, PF Schellhammer, CS Higano, CH Redfern, JJ Nemunaitis, ... Journal of Clinical Oncology 24 (19), 3089-3094, 2006 | 2196 | 2006 |
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth RB Montgomery, EA Mostaghel, R Vessella, DL Hess, TF Kalhorn, ... Cancer research 68 (11), 4447-4454, 2008 | 1722 | 2008 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1622 | 2015 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1445 | 2016 |
| Guideline for the management of clinically localized prostate cancer: 2007 update I Thompson, JB Thrasher, G Aus, AL Burnett, ED Canby-Hagino, ... The Journal of urology 177 (6), 2106-2131, 2007 | 1412 | 2007 |
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... The Lancet 375 (9724), 1437-1446, 2010 | 1328 | 2010 |
| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1317 | 2019 |
| Quantitative and stoichiometric analysis of the microRNA content of exosomes JR Chevillet, Q Kang, IK Ruf, HA Briggs, LN Vojtech, SM Hughes, ... Proceedings of the National Academy of Sciences 111 (41), 14888-14893, 2014 | 1145 | 2014 |
| Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer CS Higano, PF Schellhammer, EJ Small, PA Burch, J Nemunaitis, L Yuh, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 1003 | 2009 |
| Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized … MS Cookson, G Aus, AL Burnett, ED Canby-Hagino, AV D’Amico, ... The Journal of urology 177 (2), 540-545, 2007 | 964 | 2007 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 880* | 2018 |
| Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B Y Sun, J Campisi, C Higano, TM Beer, P Porter, I Coleman, L True, ... Nature medicine 18 (9), 1359-1368, 2012 | 880 | 2012 |
| PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine MA Cheever, CS Higano Clinical Cancer Research 17 (11), 3520-3526, 2011 | 867 | 2011 |
| Prostate cancer, version 1.2016 JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ... Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016 | 776 | 2016 |
| Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, ... Nature medicine 22 (4), 369-378, 2016 | 729 | 2016 |
